2025-12-25 - Analysis Report
Okay, here's a comprehensive analysis of Hims & Hers Health (HIMS) based on the data provided, organized as requested.

**1) Return Rate Comparison (HIMS vs. VOO)**

*   **Company Overview:** Hims & Hers Health Inc. is a telehealth company offering personalized health and wellness solutions.
*   **HIMS Cumulative Return:** 129.58%
*   **VOO Cumulative Return:** 74.84%
*   **Divergence:**
    *   Current: 54.7
    *   Relative Divergence: 34.5 (meaning it's in the lower portion of its historical divergence range compared to VOO)

**Analysis of Alpha, Beta, CAGR, MDD Table:**

| Year       | CAGR     | MDD   | Alpha   | Beta   | Cap(B) |
|------------|----------|-------|---------|--------|--------|
| 2019-2021  | -42.0%   | 74.4% | -81.0%  | 0.0    | 1.4    |
| 2020-2022  | -19.0%   | 78.6% | -18.0%  | -0.0   | 1.4    |
| 2021-2023  | -65.0%   | 78.6% | -67.0%  | -0.1   | 2.0    |
| 2022-2024  | 119.0%  | 79.4% | 98.0%   | -0.0   | 5.4    |
| 2023-2025  | 134.0%  | 80.8% | 69.0%   | 0.1    | 7.9    |

*   **CAGR:**  Highly volatile, swinging from significant losses to substantial gains. Recent performance (2022-2025 and 2023-2025) shows very strong growth.
*   **MDD:** Maximum Drawdown is consistently high, indicating significant risk and price volatility.
*   **Alpha:** Fluctuates dramatically.  The most recent periods (2022-2024 and 2023-2025) show positive alpha, meaning HIMS has outperformed its expected return based on its beta.
*   **Beta:** Generally around 0, meaning HIMS price is non-sensitive to market fluctuations (S&P500).
*   **Cap(B):** Market capitalization increasing, indicating the company has grown.

**In summary:** HIMS has significantly outperformed the S&P 500 recently, but historically it's been a very volatile stock with high risk and big swings in performance.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 35.56
*   **Last Market Data:** Price 34.67, Previous Close 34.80, Change -0.37
*   **5-day SMA:** 35.68
*   **20-day SMA:** 37.36
*   **60-day SMA:** 44.56

**Analysis:**

*   The stock price closed recently at 35.56, suggesting a rebound from the last market data point of 34.67.
*   The 5-day SMA is close to the current price, indicating a short-term equilibrium.
*   The 20-day SMA is above the current price, suggesting a short-term downtrend.
*   The 60-day SMA is significantly above the current price, indicating a longer-term downtrend.

**3) RSI, PPO, Divergence Change, Expected Return**

*   **MRI:** 0.8 (Medium Investment Recommendation)
*   **RSI:** 44.60 (Neutral - neither overbought nor oversold)
*   **PPO:** 0.0229 (Suggesting the short-term moving average is slightly above the long-term moving average)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (27 shares - Very Safe - MRI:0.90) Monthly invest 1.3% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent Divergence Change:** -2.7 (Negative = Short-Term Decline)
*   **Last Market Data:** Price decreased slightly (-0.37 change).  Reflects a small fluctuation/downtick.
*   **Expected Return:** 31.3% (Expected excess return compared to S&P 500 if invested long-term)

**Analysis:**

*   The MRI suggests a medium investment risk.
*   The RSI is neutral, indicating no immediate overbought or oversold conditions.
*   The hybrid signal suggests buying all of cash.
*   The recent negative divergence change indicates short-term downward pressure.
*   The "Expected Return" is high, suggesting potential for long-term gains.

**4) Recent News & Significant Events:**

*   **HIMS vs. TDOC Comparison:**  Comparing HIMS to Teladoc (TDOC) suggests ongoing evaluation of its competitive position in the telehealth market.
*   **Institutional Investment:** Voya Investment Management's increased stake signals confidence from a large investor.
*   **GLP-1 Concerns:** The GLP-1 "speed bump" article suggests that competition in the weight management space (potentially from GLP-1 drugs) is impacting growth, but the headline suggests the growth slowdown is manageable.
*   **Trending Stock:**  Being a "trending stock" can bring increased volatility.
*   **Analyst Highlights:** Inclusion in the Zacks Analyst Blog indicates analyst coverage and potential for price movement based on analyst opinions.

**4-2) Analyst Opinions**

*   **Consensus:**  No Key provided, but the scale is 1=StrongBuy to 5=Sell.
*   **Mean:** -
*   **Opinions:** 12 analysts covering the stock.
*   **Target Price:** Average $44.67, High $85.00, Low $25.00. A wide range suggests uncertainty or differing opinions on the stock's potential.
*   **Recent Rating Changes:** Data is missing regarding the changes, making it difficult to derive information.

**5) Recent Earnings Analysis:**

| 날짜       | EPS  | 매출    |
|------------|------|---------|
| 2025-11-03 | 0.07 | 0.60 B$ |
| 2025-08-04 | 0.19 | 0.54 B$ |
| 2025-05-05 | 0.22 | 0.59 B$ |
| 2024-11-04 | 0.35 | 0.40 B$ |
| 2025-11-03 | 0.35 | 0.40 B$ |

**Analysis:**

*   **EPS:** Declining EPS trends, which may be concerning for investors looking for consistent profitability.
*   **Revenue:** Revenue is generally increasing, which is a positive sign for growth.
*   **In summary:** Declining EPS while sales are increasing may mean the company has growing expenses.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $0.60B    | 73.80%        |
| 2025-06-30   | $0.54B    | 76.39%        |
| 2025-03-31   | $0.59B    | 73.50%        |
| 2024-12-31   | $0.48B    | 76.81%        |
| 2024-09-30   | $0.40B    | 79.16%        |

**Analysis:**

*   **Revenue:** Consistent growth in revenue.
*   **Profit Margin:** Profit Margins is high, with slight changes from 73% to 79%.

**Capital and Profitability:**

| Quarter      | Equity    | ROE      |
|--------------|-----------|----------|
| 2025-09-30   | $0.58B    | 2.72%    |
| 2025-06-30   | $0.56B    | 7.55%    |
| 2025-03-31   | $0.55B    | 9.01%    |
| 2024-12-31   | $0.48B    | 5.46%    |
| 2024-09-30   | $0.44B    | 17.18%   |

**Analysis:**

*   **Equity:** Equity is increasing over time, which is a good sign of financial health.
*   **ROE:** The returns on equity are decreasing over time, which may be concerning for investors.

**7) Comprehensive Analysis (Summary)**

Hims & Hers Health (HIMS) presents a mixed picture.

*   **Positives:**  The company is experiencing rapid revenue growth and high-profit margins, and institutional investors are increasing their stakes.  The stock has significantly outperformed the S&P 500 recently, and analysts project a high average target price (although there's a wide range of opinions). The expected return is also high at 31.3%.

*   **Negatives/Risks:**  EPS is decreasing, ROE is decreasing, and the stock is subject to high volatility. Recent news highlights competition in the telehealth and weight management spaces (specifically GLP-1 drugs). Technical indicators suggest a short-term downtrend, and the stock's historical performance shows significant drawdowns. The high MDD from the CAGR table is a huge concern.

*   **Overall:** HIMS appears to be a high-growth, high-risk stock. It may be suitable for investors with a high-risk tolerance who are willing to weather potential volatility in exchange for potentially high returns. The recent trend of declining EPS despite rising revenue is a key concern that warrants further investigation. Investors should closely monitor the company's earnings reports, competitive landscape, and analyst ratings. A potential investment may be dependent on the reasoning for the declining EPS and ROE trends.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.